Literature DB >> 7999926

Development of glycosylated human interleukin-1 alpha, neoglyco IL-1 alpha, coupled with D-mannose dimer: synthesis and biological activities in vitro.

Y Takei1, K Wada, T Chiba, H Hayashi, H Ishihara, K Onozaki.   

Abstract

Interleukin 1 (IL-1) is a nonglycosylated cytokine with pleiotropic effects on various cell types. In order to investigate the effect of carbohydrate introduction on IL-1 activity and to develop IL-1 with less deleterious effects recombinant human IL-1 alpha was chemically coupled with mannose dimers, alpha-D-Man1-6-D-Man[Man2(alpha 1,6)] and alpha-D-Man1-4-D-Man[Man2(alpha 1,4)]. About 5 molecules of mannose dimers were introduced per molecule of IL-1. Anti-IL-1 alpha antibody reacted only weakly with the glycosylated IL-1s. Conversely, antibody against the mannose dimer reacted with only glycosylated IL-1. The effect of glycosylation on IL-1 activity was evaluated by measuring a variety of IL-1 activities in vitro, including proliferative effect on T cells, antiproliferative effect on melanoma cells, stimulatory effect on IL-6 synthesis by melanoma cells, and stimulatory effect on prostaglandin E2 synthesis by fibroblast cells. Glycosylated IL-1s exhibited reduced activities, which were 10-fold to more than several hundred-fold lower than those of the original IL-1 alpha depending upon different aspects of activities addressed. Man2(alpha 1,6)-introduced IL-1 exhibited lower activity than Man2(alpha 1,4)-introduced IL-1. The competitive binding of 125I-IL-1 alpha to mouse T cells with unlabeled IL-1s suggests that the reduced activity of glycosylated IL-1s is due, at least partially, to the decrease of their receptor binding abilities.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7999926

Source DB:  PubMed          Journal:  Lymphokine Cytokine Res        ISSN: 1056-5477


  8 in total

1.  In vitro biological activities of glycosylated human interleukin-1alpha, neoglyco IL-1alpha, coupled with N-acetylneuraminic acid.

Authors:  K Moriya; T Chiba; S Nabeshima; H Hayashi; K Onozaki
Journal:  Glycoconj J       Date:  1999-09       Impact factor: 2.916

2.  Synthesis of glycosylated human interleukin-1alpha, neoglyco IL-1alpha, coupled with N-acetylneuraminic acid.

Authors:  T Chiba; K Moriya; S Nabeshima; H Hayashi; Y Kobayashi; S Sasayama; K Onozaki
Journal:  Glycoconj J       Date:  1999-09       Impact factor: 2.916

3.  Development of glycosylated human interleukin-1alpha, neoglyco IL-1alpha, by coupling with D-galactose monosaccharide: biological activities in vitro.

Authors:  S Nabeshima; T Chiba; Y Takei; S Watanabe; H Okuyama; K Onozaki
Journal:  Glycoconj J       Date:  1998-01       Impact factor: 2.916

4.  Development of glycosylated human interleukin-1alpha, neoglyco IL-1alpha, by coupling with D-galactose monosaccharide: synthesis and purification.

Authors:  T Chiba; S Nabeshima; Y Takei; K Onozaki
Journal:  Glycoconj J       Date:  1998-01       Impact factor: 2.916

5.  Development of glycosylated human interleukin-1alpha, neoglyco IL-1alpha, coupled with D-galactose monosaccharide: biological activities in vivo.

Authors:  S Nabeshima; T Chiba; Y Takei; A Ono; K Moriya; K Onozaki
Journal:  Glycoconj J       Date:  1998-05       Impact factor: 2.916

6.  Synthesis and biological activities in vitro and in vivo of glycosylated human interleukin-1alpha, neoglyco IL-1alpha, coupled with N -acetylneuraminyl-galactose.

Authors:  Masaaki Ootsubo; Taku Chiba; Yutaka Kobayashi; Hidetoshi Hayashi; Akiko Hayashi; Kikuo Onozaki
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

7.  N-acetylneuraminic acid coupled human recombinant TNFalpha exhibits enhanced anti-tumor activity against Meth-A fibrosarcoma and reduced toxicity.

Authors:  Akiko Hayashi; Hidetoshi Hayashi; Taku Chiba; Satoshi Sasayama; Kikuo Onozaki
Journal:  Cancer Immunol Immunother       Date:  2006-10-10       Impact factor: 6.968

8.  Glycosylated human interleukin-1alpha, neoglyco IL-1alpha, coupled with N-acetylneuraminic acid exhibits selective activities in vivo and altered tissue distribution.

Authors:  S Sasayama; K Moriya; T Chiba; T Matsumura; H Hayashi; A Hayashi; K Onozaki
Journal:  Glycoconj J       Date:  2000-06       Impact factor: 2.916

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.